Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Neuroscience Solution

Neither a doctor nor a teaching hospital

Research payments

$1,298,329

207 payments

Through program year 2025, Clinical Neuroscience Solution is reported as receiving $1,298,329 in research payments, across 207 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $64,240 29
2024 Research $18,967 6
2023 Research $22 1
2022 Research $448,266 52
2021 Research $138,959 14
2020 Research $589,218 80
2019 Research $38,655 25

Breakdown

Who paid Research payments · program years 2019–2025
  1. Purdue Pharma L.P. $581,667 49 payments
  2. Sage Therapeutics, Inc. $384,953 32 payments
  3. Teva Pharmaceuticals USA, Inc. $219,720 52 payments
  4. Moderna TX, Inc. $54,137 21 payments
  5. Sumitomo Pharma America, Inc. $29,071 14 payments
  6. Paratek Pharmaceuticals, Inc. $11,176 7 payments
  7. Allergan Inc. $6,325 10 payments
  8. Swedish Orphan Biovitrum AB $4,579 1 payment
  9. H. Lundbeck A S $2,979 2 payments
  10. Amneal Pharmaceuticals LLC $2,000 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. An open-label, multicenter, multiple-dose, safety and tolerability study of Adhansia XR extended-release capsules in children 4 to 12 years of age $581,690 50 payments
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder $209,582 44 payments
  3. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $200,170 6 payments
  4. 217-Mdd-302 $133,087 14 payments
  5. A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age $54,137 21 payments
  6. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $29,071 14 payments
  7. 217-Mdd-301 $25,532 7 payments
  8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Sage-217 With A Fixed, Repeated Treatment Regimen on Relapse Prevention in Adults With Major Depressive Disorder $24,164 4 payments
  9. A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of Oral Omadacycline and Oral Nitrofurantoin in the Treatment of Female Adults With Cystitis $11,176 7 payments
  10. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments $10,138 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record